https://basecall.news The definitive read en-us Thu, 09 Apr 2026 20:51:30 GMT https://basecall.news/article/oxford-nanopore-clinical-validation-studies-2026-03-27.html https://basecall.news/article/oxford-nanopore-clinical-validation-studies-2026-03-27.html Thu, 09 Apr 2026 17:13:50 GMT A deep-learning methylation classifier for pediatric cancers and a unified PCR/nanopore carrier screening assay demonstrate clinical-grade performance, positioning the platform against Illumina microarrays and legacy PCR workflows. https://basecall.news/article/tempus-ai-gilead-rwd-partnership-2026-04-09.html https://basecall.news/article/tempus-ai-gilead-rwd-partnership-2026-04-09.html Thu, 09 Apr 2026 17:12:30 GMT The deal underscores pharma demand for clinical genomic datasets to inform oncology drug development and positions Tempus's data-licensing model as a differentiator. https://basecall.news/article/sophia-genetics-qiagen-ngs-partnership-2026-04-08.html https://basecall.news/article/sophia-genetics-qiagen-ngs-partnership-2026-04-08.html Thu, 09 Apr 2026 17:02:33 GMT The collaboration pairs Qiagen's sample-prep reagents with Sophia Genetics' AI-driven analytics platform. https://basecall.news/article/roche-50b-us-investment-2026-04-08.html https://basecall.news/article/roche-50b-us-investment-2026-04-08.html Thu, 09 Apr 2026 17:01:13 GMT The commitment arrives amid trade policy uncertainty, though the company has not disclosed a timeline or breakdown between manufacturing and R&D spending. https://basecall.news/article/quest-diagnostics-guidance-raise-2026-04-09.html https://basecall.news/article/quest-diagnostics-guidance-raise-2026-04-09.html Thu, 09 Apr 2026 17:00:20 GMT The company beat Q1 2025 estimates and issued dual-year guidance above consensus, signaling durable commercial lab utilization as sequencing and diagnostics peers face margin pressure. https://basecall.news/article/oxford-nanopore-diagnostic-approval-uk-europe-2026-04-08.html https://basecall.news/article/oxford-nanopore-diagnostic-approval-uk-europe-2026-04-08.html Thu, 09 Apr 2026 16:58:20 GMT The regulatory clearance marks the sequencing company's entry into clinical diagnostics, though the device name and indication were not disclosed. https://basecall.news/article/mgi-tech-us-divestiture-2026-04-08.html https://basecall.news/article/mgi-tech-us-divestiture-2026-04-08.html Thu, 09 Apr 2026 16:55:29 GMT The Chinese sequencing vendor's exit from direct U.S. operations removes a low-cost competitor as Illumina faces its own China sales ban. https://basecall.news/article/guardant-patent-verdict-illumina-settlement-2026-04-08.html https://basecall.news/article/guardant-patent-verdict-illumina-settlement-2026-04-08.html Thu, 09 Apr 2026 16:54:07 GMT The jury award and separate settlement with Illumina highlight ongoing IP exposure in the liquid biopsy sector. Financial terms of the Illumina deal were not disclosed. https://basecall.news/article/grail-ceo-succession-ofman-2026-03-13.html https://basecall.news/article/grail-ceo-succession-ofman-2026-03-13.html Thu, 09 Apr 2026 16:52:29 GMT The leadership transition, effective June 1, follows Galleri's NHS trial endpoint miss and hands the reins to the executive who led the company's clinical evidence and reimbursement strategy. https://basecall.news/article/grail-epic-ehr-galleri-integration-2026-04-07.html https://basecall.news/article/grail-epic-ehr-galleri-integration-2026-04-07.html Thu, 09 Apr 2026 16:51:28 GMT The partnership gives approximately 450 health systems point-of-care ordering capability for the multi-cancer early detection test within Epic's native workflow. https://basecall.news/article/waters-fda-hpv-home-collection-clearance-2026-04-08.html https://basecall.news/article/waters-fda-hpv-home-collection-clearance-2026-04-08.html Thu, 09 Apr 2026 16:48:22 GMT The 510(k) clearance pairs the company's Onclarity HPV assay with a patient self-collection workflow, expanding Waters' molecular diagnostics footprint into consumer-initiated cervical cancer screening. https://basecall.news/article/grail-nhs-trial-endpoint-miss-2026-04-08.html https://basecall.news/article/grail-nhs-trial-endpoint-miss-2026-04-08.html Wed, 08 Apr 2026 23:53:30 GMT The endpoint miss in the UK trial raises questions about commercial viability of multicancer early detection screening, though some UK clinicians continue offering early access pending full data readout. https://basecall.news/article/23andme-glp1-pharmacogenomics-study-2026-04-08.html https://basecall.news/article/23andme-glp1-pharmacogenomics-study-2026-04-08.html Wed, 08 Apr 2026 18:05:19 GMT The bankrupt consumer genomics company published research identifying genetic variants affecting efficacy and side effects of obesity drugs, though clinical validation and regulatory details remain undisclosed. https://basecall.news/article/grail-mced-cost-effectiveness-modeling-2026-04-08.html https://basecall.news/article/grail-mced-cost-effectiveness-modeling-2026-04-08.html 2026-04-08T07:33:56-04:00 Two health-economic models quantify infrastructure demands and reimbursement thresholds for multi-cancer screening at population scale, as GRAIL navigates NHS trial failure and regulatory divestiture from Illumina. https://basecall.news/article/hologic-blackstone-tpg-buyout-closes-2026-04-07.html https://basecall.news/article/hologic-blackstone-tpg-buyout-closes-2026-04-07.html 2026-04-06T10:49:44-04:00 The leveraged buyout closed Tuesday with $12 billion in debt financing. Steve MacMillan steps down after nearly 13 years as CEO; former Baxter chief José Almeida named successor. https://basecall.news/article/myriad-mychoice-fda-approval-2026-03-19.html https://basecall.news/article/myriad-mychoice-fda-approval-2026-03-19.html Tue, 17 Mar 2026 07:00:00 GMT The companion diagnostic uses homologous recombination deficiency scoring to identify patients who may benefit from PARP inhibitor therapy.